Usona files psilocybin drug for depression as race with Compass tightens
Usona files psilocybin drug for depression as race with Compass tightens
Usona files psilocybin drug for depression as race with Compass tightens
Key points
اہم نکات
मुख्य बातें
- Usona has filed its application for a psilocybin-based treatment for depression, stepping up the race with rival Compass to bring a psychedelic medicine to patients.
- The filing marks a key step toward regulatory review, in a field where several companies are competing to turn psychedelic compounds into approved mental health treatments.
- Usona has filed its application for a psilocybin-based treatment for depression, stepping up the race with rival Compass to bring a psychedelic medicine to patients.
- The filing marks a key step toward regulatory review, in a field where several companies are competing to turn psychedelic compounds into approved mental health treatments.
- Usona has filed its application for a psilocybin-based treatment for depression, stepping up the race with rival Compass to bring a psychedelic medicine to patients.
- The filing marks a key step toward regulatory review, in a field where several companies are competing to turn psychedelic compounds into approved mental health treatments.
Usona has filed its application for a psilocybin-based treatment for depression, stepping up the race with rival Compass to bring a psychedelic medicine to patients. The filing marks a key step toward regulatory review, in a field where several companies are competing to turn psychedelic compounds into approved mental health treatments.
Usona has filed its application for a psilocybin-based treatment for depression, stepping up the race with rival Compass to bring a psychedelic medicine to patients. The filing marks a key step toward regulatory review, in a field where several companies are competing to turn psychedelic compounds into approved mental health treatments.
Usona has filed its application for a psilocybin-based treatment for depression, stepping up the race with rival Compass to bring a psychedelic medicine to patients. The filing marks a key step toward regulatory review, in a field where several companies are competing to turn psychedelic compounds into approved mental health treatments.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।